[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354330-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354330-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-ctdna-dynamics-predict-response-to-mosperafenib-in-braf-v600-mutant-metastatic-colorectal-cancer","Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer","","The serine–threonine protein kinase B-RAF V600 mutation confers poor prognosis in metastatic colorectal cancer, and mosperafenib is a novel paradox-breaking BRAF inhibitor. In a phase I study, circulating tumor DNA (ctDNA) was assessed as a prognostic and predictive biomarker for mosperafenib monotherapy in 49 biomarker-evaluable patients. Baseline ctDNA quantified by tumor-naive and tumor-informed assays correlated with RECIST 1.1 response and progression-free survival. Low baseline ctDNA predicted longer mPFS, and a ≥75% ctDNA reduction at C1D15 strongly predicted durable benefit, mainly in BRAFi-naive patients, while MAPK pathway resistance mutations were common in BRAFi-experienced disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-ctdna-dynamics-predict-response-to-mosperafenib-in-braf-v600-mutant-metastatic-colorectal-cancer/354330/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-ctdna-dynamics-predict-response-to-mosperafenib-in-braf-v600-mutant-metastatic-colorectal-cancer/354330.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does ctDNA play in predicting mosperafenib response in BRAF V600-mutant metastatic colorectal cancer?","Question",{"text":63,"@type":64},"ctDNA was evaluated as both a prognostic and predictive biomarker. Low baseline ctDNA associated with longer progression-free survival, and early deep molecular reductions predicted durable clinical benefit.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is molecular response defined in the study?",{"text":68,"@type":64},"Molecular response was defined as a ≥75% reduction in ctDNA at cycle 1 day 15 (C1D15). This metric correlated with longer mPFS.",{"name":70,"@type":61,"acceptedAnswer":71},"Do early ctDNA dynamics predict response equally across BRAFi-naive and BRAFi-experienced patients?",{"text":72,"@type":64},"The early deep molecular response was largely confined to BRAFi-naive patients, while BRAFi-experienced patients showed less frequent response. Preexisting MAPK pathway resistance mutations in the BRAFi-experienced cohort were associated with poor outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354330,1790201536,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-26-0196](https://doi.org/10.1158/2767-9764.CRC-26-0196)  OPEN ACCESS  \nEarly ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer  \nMartha Liliana Serrano-Serrano1, Christina Godfried Sie1, Oliver Bechter2, Giulia Pretelli3, Mara Vieito3, Elisa Fontana4, Catherine H. Han5, Eduardo Castañn ´Alvarez6, Ignacio Matos6, David J. Pinato7,8, Irene Moreno9, Rikke L. Eefsen10, Ruth Plummer11, Reinhard Dummer12, Hans Prenen13, Joseph Sutton14, Elisa Cinato1, Gabriel Schnetzler1, Nino Keshelava15, and Andreas Roller1  \n􀀶  \nABSTRACT  \nThe serine–threonine protein kinase B-RAF (BRAF) V600 mutation confers a poor prognosis in metastatic colorectal cancer (mCRC) . Mosperafenib is a novel, paradox-breaking BRAF inhibitor (BRAFi) . In this analysis of a phase I study (ISRCTN13713551), we evaluated circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker for mosperafenib monotherapy in BRAF V600-mutant mCRC. We analyzed 49 biomarker-evaluable patients with mCRC (BRAF V600-mutant; 23 BRAFi-naive, and 26 BRAFi-experienced) . Plasma samples were collected at baseline and longitudinally. ctDNA levels were quantified using tumor-naive and tumor-informed assays and correlated with RECIST 1.1 response and progression-free survival (PFS) . Mutational profiles were assessed to identify resistance mechanisms. Low baseline ctDNA (≤10% tumor fraction) was prognostic for longer median PFS (mPFS; 284 vs. 59 days; HR ¼ 0.32, P ¼ 0.00051). Early ctDNA dynamics were highly predictive; a ≥75% ctDNA reduction at cycle 1 day 15 (C1D15;“molecular response”) correlated with longer mPFS (281 vs. 43 days, P \u003C 0.0001). This molecular response occurred in all BRAFi-naive patients  \nversus 48% of BRAFi-experienced patients. Preexisting MAPK pathway resistance mutations were prevalent and prognostic for poor outcomesin the BRAFi-experienced cohort (HR ¼ 3.5, P ¼ 0.003), whereas BRAFi-naive patients acquired these at progression. ctDNA is a powerful biomarker for mosperafenib-treated BRAF V600-mutated mCRC. Low baseline ctDNA is highly prognostic, whereas an early, deep molecular response at C1D15 predicts durable benefit. This response is largely confined to BRAFi-naive patients, as preexisting MAPK pathway alterations in BRAFi-experienced patients correlate with lack of response. These findings support using early ctDNA dynamics as an efficacy endpoint in future trials.  \nSignificance: This study in BRAF V600-mutant mCRC treated with mosperafenib confirms ctDNA’s translational utility. Low baseline ctDNA associated with longer PFS and an early deep molecular response predicted durable clinical benefit, supporting its use as an early efficacy endpoint. In addition, ctDNA monitoring enables identification of resistance mechanisms.  \nIntroduction  \nMetastatic colorectal cancer (mCRC) remains a leading cause of cancerrelated mortality worldwide. Mutations at valine 600 in the serine–threonine protein kinase B-RAF (BRAF) is observed in 8% to 12% of patients with  \n1Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. 2 University Hospitals Leuven, Leuven, Belgium. 3Valld’Hebron University Hospital, Barcelona, Spain. 4Sarah Cannon Research Institute, London, United Kingdom. 5 New Zealand Clinical Research, Auckland City Hospital, Auckland, New Zealand. 6Clinica Universidad de Navarra, Madrid, Spain. 7 Imperial College London, Hammersmith Hospital, London, United Kingdom. 8University of Piemonte Orientale, Novara, Italy. 9START Madrid-Centro Integral Oncolgico Clara Campal (CIOCC), Hospital Universitario HM, Madrid, Spain. 10 Department of Oncology, Herlev Gentofte Hospital, Copenhagen, Denmark. 11 Newcastle Hospitals NHS Foundation Trust, Newcastle University, Newcastle, United Kingdom. 12Universittsspital Zrich, Zrich, Switzerland. 13University Hospital Antwerp, Edegem, Belgium. 14 Roche  \nmCRC and presents a negative pr","cbCaivyppU8IfpOj","https://ap.wps.com/l/cbCaivyppU8IfpOj","pdf",5933627,12,"English","# Abstract\n# Introduction\n## BRAF V600 mutation and MAPK signaling\n## Paradoxical MAPK reactivation and therapy context\n## Mosperafenib and study rationale\n# Study approach and biomarker evaluation\n## ctDNA sampling and quantification\n## RECIST 1.1 and progression-free survival correlations\n## Resistance mutation profiling","[{\"question\":\"What role does ctDNA play in predicting mosperafenib response in BRAF V600-mutant metastatic colorectal cancer?\",\"answer\":\"ctDNA was evaluated as both a prognostic and predictive biomarker. Low baseline ctDNA associated with longer progression-free survival, and early deep molecular reductions predicted durable clinical benefit.\"},{\"question\":\"How is molecular response defined in the study?\",\"answer\":\"Molecular response was defined as a ≥75% reduction in ctDNA at cycle 1 day 15 (C1D15). This metric correlated with longer mPFS.\"},{\"question\":\"Do early ctDNA dynamics predict response equally across BRAFi-naive and BRAFi-experienced patients?\",\"answer\":\"The early deep molecular response was largely confined to BRAFi-naive patients, while BRAFi-experienced patients showed less frequent response. Preexisting MAPK pathway resistance mutations in the BRAFi-experienced cohort were associated with poor outcomes.\"}]","Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer | PDF",1790110144,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e72c3b6e455a8a187dcb313a678cb970.webp",983,1263,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec75c024a18d5024f94ac7c47ef874d2.webp",982,1262,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24c96ed14f9f26967f99c3053f8f234f.webp",981,1261,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5c45f0b08d40de8110e9c356a4ab6ca.webp",980,1259]